Innovation Pharmaceuticals Inc (IPIX)

[slcimmuno]

thx for the recap. T-bactin's Boston-area connection prob helped for sure--gave NEJM an oppty to address the ABX resistance bugaboo. when news broke in Jan, the iCHIP method did seem to be of most interest to academic types.

also excited to get an update on the Gram- rsch at ECCMID in Copenhagen. again, with a regulatory push for pathogen-specific drugs, it's likely if/when B gets approved, follow-on HDP-Ms might get to market m sooner--fewer, smaller, shorter studies. my guess B might make it to market in the latter part of 2016 at earliest.

below a recap on the Boston Area Antimicrobial Research Network event you had mentioned. covers ABX scene, in particular, the recent pinkslips in Mass.

Research cuts ripple across biopharma sector
http://www.bostonglobe.com/business/2015/03/18/some-fear-wave-biopharma-research-cuts-could-slow-progress-fighting-infectious-diseases/10lDVFIuUAJs9oLrqA3AIO/story.html

EXCERPTS
More than 200 infectious disease researchers from the Boston area converged at the Broad Institute of MIT and Harvard last week to swap business cards and drug discovery ideas and talk about the biggest medical challenges ahead.But as they gathered, two biopharmaceutical companies working on anti-infective treatments, Merck & Co. and AstraZeneca PLC, were preparing to shed about 200 employees from research and development labs in Lexington and Waltham. The Merck and AstraZeneca moves, part of a wave of research cutbacks rippling through the industry, have alarmed scientists, who fear a slowdown in experimental therapies on many fronts. Whether it is just a blip, or a signal that Boston’s biotech industry is cooling, remains to be seen.
[...]
On the bright side, more startups and newly public companies have been entering the anti-infective drug business, including Paratek, Tetraphase Pharmaceuticals of Watertown, Spero Therapeutics of Cambridge, and NovoBiotic Pharmaceuticals in Cambridge. “It’s a better time for people in this field,” said Aileen Rubio, director of in vitro biology at Cubist, who will be losing her job in the cutback. “There’s more companies doing this work.” Longtime industry watchers say the latest cuts mirror actions of the past, when researchers were displaced by big drug company mergers but landed at other firms and continued to pursue drug discovery in their fields. Indeed, Loh and some of his Paratek colleagues are veterans of Wyeth, a drug company acquired by Pfizer in 2009. “There’s been a dearth of Big Pharma innovation in antibiotics,” said Loh. “The innovation has fallen on the shoulders of the smaller biotechs and we're excited about it.”